In a patient with bacterial sepsis who has developed hepatitis, should intravenous immunoglobulin (IVIG) be administered?

IVIG Should Not Be Administered in Bacterial Sepsis with Hepatitis

Do not administer IVIG to this patient—the Surviving Sepsis Campaign explicitly recommends against routine IVIG use in sepsis and septic shock, and high-quality randomized controlled trials demonstrate no mortality benefit. 1

Guideline-Based Recommendation Against IVIG

• The Surviving Sepsis Campaign international guidelines provide a weak recommendation against routine IVIG in both adult and pediatric patients with sepsis or septic shock, based on low-quality evidence. 1

• A large randomized controlled trial enrolling 624 adult patients with severe sepsis found no clinical benefit from IVIG therapy, providing Level I evidence against its use. 1

• When meta-analyses are restricted to high-quality studies with low risk of bias, IVIG does not reduce mortality (Risk Ratio 0.97; 95% CI 0.81–1.15). 1

Why IVIG Fails in Routine Sepsis

• The evidence base suffers from considerable heterogeneity in dosing regimens, immunoglobulin preparation types (standard IgG vs. IgM-enriched), control interventions, and study quality. 1, 2

• IVIG preparations exhibit batch-to-batch variability in antibody content and biologic activity, making standardized treatment recommendations impossible. 1, 2

• Critical confounding factors are not addressed in existing trials: baseline patient immunoglobulin levels, presence of pathogen-specific antibodies, accuracy of antibiotic selection, and degree of sepsis-induced immunosuppression. 2

• The most recent 2025 retrospective study of 50 patients with extensively drug-resistant bacterial sepsis showed no difference in 30-day mortality (71.4% with IVIG vs. 77.3% without, P=0.886) or ICU length of stay. 3

Additional Risk in Hepatitis Context

• Patients with hepatitis may have volume depletion and altered hepatic synthetic function, predisposing them to renal hypoperfusion when IVIG is administered. 1

• Septic shock creates a hypercoagulable state that IVIG can exacerbate, increasing thrombotic complications. 1

• The presence of hepatitis does not change the fundamental lack of efficacy demonstrated in high-quality sepsis trials. 1, 3

Specific Exceptions Where IVIG May Be Considered

• Toxic shock syndrome, particularly streptococcal etiology, represents the primary indication where IVIG may provide benefit. 1, 4

• Necrotizing fasciitis may warrant IVIG consideration, though adult evidence does not consistently support this use. 1

• Primary humoral immunodeficiencies or documented low immunoglobulin levels in immunocompromised patients may justify IVIG replacement therapy. 1, 4

• These exceptions do not apply to routine bacterial sepsis with hepatitis. 1

IgM-Enriched Preparations Do Not Change the Recommendation

• Some lower-quality meta-analyses suggest IgM-enriched IVIG (IgGAM) may show stronger benefit than standard IgG-only preparations. 1, 4

• However, when analysis is restricted to high-quality trials, even IgM-enriched preparations demonstrate no mortality benefit. 1, 4

• The apparent benefit in meta-analyses disappears when methodological rigor is applied. 4

Low-Dose IVIG Does Not Improve Outcomes

• A 2022 Japanese study of low-dose IVIG (5 g/day for 3 days, total 0.3 g/kg) in septic shock showed no survival benefit regardless of baseline serum IgG levels. 5

• Patients with hypogammaglobulinemia (<830 mg/dL) had 28-day survival of 85.0% vs. 90.0% in those with normal IgG (P=0.457), demonstrating that serum IgG levels do not predict IVIG efficacy. 5

• Neither artificial ventilation duration nor ICU length of stay differed between groups. 5

Common Pitfalls to Avoid

• Relying on older, lower-quality studies that show benefit while ignoring the large, high-quality RCT demonstrating no effect. 1, 4

• Using IVIG as a routine adjunctive therapy for all sepsis patients rather than targeting the specific subpopulations (toxic shock syndrome, documented immunodeficiency) who might benefit. 1, 4

• Assuming hepatitis or other organ dysfunction creates a special indication for IVIG when no evidence supports this approach. 1

• Misinterpreting meta-analyses that include heterogeneous, low-quality studies as evidence for IVIG efficacy. 1, 2

Focus on Evidence-Based Sepsis Management Instead

• Administer broad-spectrum antibiotics within one hour of sepsis recognition, ensuring coverage of all likely pathogens. 6

• Provide appropriate source control, adequate fluid resuscitation, and vasopressor support according to Surviving Sepsis Campaign guidelines. 6

• Obtain blood cultures before antibiotics (at least two sets) and reassess daily for de-escalation based on susceptibility results. 6

• Plan for 7–10 days of antibiotic therapy for most serious infections, with extensions for slow clinical response or specific pathogens like Staphylococcus aureus bacteremia. 6